Opioid Induced Constipation Market Share, Size, Trends, Industry Analysis Report, By Active Ingredients; By Prescription Type; By Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032

Opioid Induced Constipation Market Share, Size, Trends, Industry Analysis Report, By Active Ingredients; By Prescription Type; By Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032

The global opioid induced constipation market size is expected to reach USD 3.93 billion by 2032, according to a new study by Polaris Market Research. The report “Opioid Induced Constipation Market Share, Size, Trends, Industry Analysis Report, By Active Ingredients; By Prescription Type; By Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Opioids are most used to get relief from pain, as they include morphine, tramadol, and fentanyl. The increased accessibility of painkillers at retail and online e-commerce platforms is showing a positive impact on the demand for opioids in the marketplace, including significant growth potential for opioid-induced constipation.

The rising awareness campaigns by pharmaceutical companies, governments, and non-government agencies are demonstrating a positive impact on the opioid-induced constipation market. For instance, in 2023, Salix Pharmaceuticals, a drug manufacturer, along with the other two non-profit organisations, declared December 5 as the opioid-induced constipation awareness day to confront the stigmas surrounding the issue.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/opioid-induced-constipation-market/request-for-sample

The rising use of opioids among the larger consumer base is expected to boost demand for opioid-induced constipation treatment. According to the available data, among the individuals who consumed opioids without cancer, around 40–60% of the people get opioid-induced constipation (OIC).

The higher risk of constipation with the intake of opioid-related drugs, along with the growing research studies to review the potential causes and suitable treatments, are showing wider growth opportunities for the market. For instance, a study published in the National Library of Medicine explored opioid-induced constipation and reviewed potential therapeutic and non-therapeutic treatments to treat the disease.

Furthermore, the use of opioids can be related to the rising use by cancer patients to get pain relief. According to pharmaceutical experts, approximately 60 to 90% of patients who took the opioid for cancer treatment suffered from opioid-induced constipation. Opioid-induced constipation patients are likely to face more difficulties in day-to-day life activities, primarily those facing cancer pain.

Moreover, research activities are positively influencing the creation of effective treatments for patients suffering from opioid-induced constipation. For instance, a 2024 study focused on finding the relationship between opioid-induced constipation and the P2Y1 receptor in the colonic myenteric plexus of rats.

Opioid Induced Constipation Market Report Highlights

Naloxegol segment will grow at the fastest pace, due to its potential for treating opioid induced constipation issues.

Prescription segment held the largest share, owing to the rising importance of doctor consultation.

Oral segment dominated the market, primarily due to its ease of treatment intake and higher effectiveness.

Asia Pacific will register the fastest pace, attributable to the presence of the large proportion of elderly population.

The global players include Abbott, Aurobindo Pharma, Bayer, Boehringer Ingelheim International, & Bristol Myers Squibb Company.

Polaris Market Research has segmented the opioid induced constipation market report based on active ingredients, prescription type, route of administration, distribution channel and region:

Opioid Induced Constipation, Active Ingredients Outlook (Revenue - USD Billion, 2019 - 2032)

Naloxegol

Lubiprostone

Methylnaltrexone Bromide

Docusate Sodium

Others

Opioid Induced Constipation, Prescription Type Outlook (Revenue - USD Billion, 2019 - 2032)

Over The Counter Medicines

Prescription, Natural Remedies

Opioid Induced Constipation, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)

Oral

Injectable

Others

Opioid Induced Constipation, Distribution Channel Outlook (Revenue - USD Billion, 2019 - 2032)

Hospital Pharmacy

Online Pharmacy

Retail Pharmacy

Opioid Induced Constipation, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

North America

• U.S.
• Canada

Europe

• Germany
• UK
• France
• Italy
• Spain
• Russia
• Netherlands

Asia Pacific

• China
• India
• Japan
• South Korea
• Indonesia
• Malaysia

Latin America

• Argentina
• Brazil
• Mexico

Middle East & Africa

• UAE
• Saudi Arabia
• Israel
• South Africa